PEG RELIGRAST 6mg PFS contains the active substance Pegfilgrastim 6mg. It belongs to a group of medicines known as Granulocyte Colony-Stimulating Factors (G-CSF). It is primarily used to reduce the risk of infection and febrile neutropenia (low white blood cell count with fever) in cancer patients receiving chemotherapy. Pegfilgrastim stimulates the bone marrow to produce more neutrophils, a type of white blood cell that helps fight infections.
PEG RELIGRAST is supplied as a 0.6ml prefilled syringe (PFS) and is generally administered after chemotherapy cycles to help restore white blood cell levels and reduce infection-related complications.
Uses of PEG RELIGRAST 6mg PFS
- Prevention of Chemotherapy-Induced Neutropenia
- Reduction of Febrile Neutropenia Risk
- Prevention of Serious Infections During Cancer Treatment
- Support of White Blood Cell Recovery After Chemotherapy
- Improvement of Immune Function in Cancer Patients
Therapeutic Effects of PEG RELIGRAST 6mg PFS
PEG RELIGRAST works by binding to G-CSF receptors in the bone marrow and stimulating the growth, maturation, and release of neutrophils into the bloodstream. This helps restore the body's natural defense against infections during chemotherapy treatment.
Interaction of PEG RELIGRAST 6mg PFS with Other Drugs
It is important to inform your healthcare professional about all medicines you are taking.
Notable interactions include:
- Chemotherapy Medicines
- Bone Marrow Suppressing Drugs
- Immunosuppressants
- Hydroxyurea
- Azathioprine
- Other Colony-Stimulating Factors
More Information about PEG RELIGRAST 6mg PFS
- Keep out of reach of children.
- Store in a refrigerator at 2°C–8°C.
- Do not freeze.
- Protect from light.
- Keep in original packaging until use.
- Do not shake the syringe.
How to Consume PEG RELIGRAST 6mg PFS
PEG RELIGRAST is administered as a subcutaneous (under the skin) injection by a healthcare professional.
It is typically given at least 24 hours after chemotherapy. The dosage and schedule are determined by the treating oncologist based on the chemotherapy regimen and patient condition.
Safety Advice for PEG RELIGRAST 6mg PFS
Breast Feeding
Not Recommended
Consult your doctor before using this medicine while breastfeeding.
Alcohol
Consult Your Doctor
Alcohol interaction is not well established.
Liver
Caution
Use under medical supervision in patients with liver disease.
Kidneys
Caution
Patients with kidney disorders should be monitored carefully.
Driving
Generally Safe
Usually has little or no effect on driving ability, but avoid driving if dizziness occurs.
Pregnancy
Use Only on Medical Advice
Not generally recommended during pregnancy unless clearly necessary.
Side Effects of PEG RELIGRAST 6mg PFS
Side effects are unwanted symptoms caused by medicines. Although not everyone experiences them, some patients may develop side effects.
Common Side Effects of PEG RELIGRAST 6mg PFS
- Bone Pain
- Muscle Pain
- Joint Pain
- Headache
- Nausea
- Injection Site Reactions
- Fatigue
Serious Side Effects of PEG RELIGRAST 6mg PFS
- Severe Allergic Reactions
- Acute Respiratory Distress Syndrome (ARDS)
- Spleen Enlargement or Rupture
- Severe Breathing Difficulties
- Sickle Cell Crisis (in susceptible patients)
- Capillary Leak Syndrome
Word of Advice
PEG RELIGRAST 6mg PFS plays an important role in reducing infection risk during chemotherapy. Patients should report fever, breathing difficulties, severe bone pain, abdominal pain, or signs of allergic reactions immediately. Regular blood count monitoring is recommended throughout treatment. Avoid crowded places and maintain good hygiene practices during chemotherapy to further reduce infection risk.
FAQs about PEG RELIGRAST 6mg PFS
Q1. What is PEG RELIGRAST 6mg PFS used for?
It is used to reduce the risk of infections and febrile neutropenia in cancer patients receiving chemotherapy.
Q2. How does PEG RELIGRAST work?
It stimulates the bone marrow to produce more neutrophils (white blood cells), helping the body fight infections.
Q3. When is PEG RELIGRAST administered?
It is usually given at least 24 hours after chemotherapy treatment.
Q4. Does PEG RELIGRAST require refrigeration?
Yes. It should be stored at 2°C–8°C and protected from freezing.
Q5. What is the most common side effect?
Bone pain is one of the most commonly reported side effects of Pegfilgrastim therapy.
Fact Box of PEG RELIGRAST 6mg PFS
Molecule Name: Pegfilgrastim 6mg
Therapeutic Class: Hematopoietic Growth Factors
Pharmacological Class: Granulocyte Colony-Stimulating Factor (G-CSF)
Indications: Chemotherapy-Induced Neutropenia, Febrile Neutropenia Prevention, Infection Prevention During Cancer Therapy, White Blood Cell Recovery Support.
